PRIGNANO, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.623
EU - Europa 6.943
AS - Asia 6.534
SA - Sud America 1.313
AF - Africa 229
OC - Oceania 79
Continente sconosciuto - Info sul continente non disponibili 1
Totale 25.722
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.432
RU - Federazione Russa 2.621
SG - Singapore 1.811
CN - Cina 1.598
PL - Polonia 1.122
BR - Brasile 1.046
IT - Italia 997
HK - Hong Kong 915
VN - Vietnam 802
IE - Irlanda 610
KR - Corea 528
SE - Svezia 448
DE - Germania 298
FR - Francia 239
FI - Finlandia 210
IN - India 163
BD - Bangladesh 160
JP - Giappone 145
GB - Regno Unito 117
AR - Argentina 98
CI - Costa d'Avorio 98
CA - Canada 92
JO - Giordania 83
ID - Indonesia 80
AU - Australia 76
UA - Ucraina 74
TR - Turchia 48
MX - Messico 47
EC - Ecuador 46
CH - Svizzera 45
IQ - Iraq 45
NL - Olanda 40
CO - Colombia 35
ZA - Sudafrica 29
PY - Paraguay 25
UZ - Uzbekistan 22
ES - Italia 21
PK - Pakistan 20
VE - Venezuela 19
EG - Egitto 18
AE - Emirati Arabi Uniti 17
KE - Kenya 17
CL - Cile 16
MA - Marocco 16
SA - Arabia Saudita 16
NG - Nigeria 15
BE - Belgio 14
JM - Giamaica 14
CZ - Repubblica Ceca 11
PE - Perù 11
AT - Austria 9
DO - Repubblica Dominicana 9
AZ - Azerbaigian 8
BO - Bolivia 8
MY - Malesia 8
NP - Nepal 8
PH - Filippine 8
UY - Uruguay 8
DZ - Algeria 7
HN - Honduras 7
HR - Croazia 7
LT - Lituania 7
OM - Oman 7
RO - Romania 7
AL - Albania 6
BJ - Benin 6
DK - Danimarca 6
IR - Iran 6
TN - Tunisia 6
GT - Guatemala 5
IL - Israele 5
SV - El Salvador 5
BY - Bielorussia 4
GR - Grecia 4
NO - Norvegia 4
PA - Panama 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
TW - Taiwan 4
KG - Kirghizistan 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
PT - Portogallo 3
RS - Serbia 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BH - Bahrain 2
CR - Costa Rica 2
ET - Etiopia 2
HU - Ungheria 2
KH - Cambogia 2
LK - Sri Lanka 2
MN - Mongolia 2
PR - Porto Rico 2
RE - Reunion 2
SM - San Marino 2
AO - Angola 1
Totale 25.700
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.430
Singapore 1.271
Ashburn 1.203
Warsaw 1.113
Hong Kong 760
Dublin 604
Fairfield 585
Chandler 553
Seoul 525
San Jose 363
Buffalo 316
Hefei 300
Beijing 294
Ho Chi Minh City 283
Woodbridge 277
Lawrence 274
Altamura 272
The Dalles 258
Seattle 223
Houston 222
Wilmington 221
Cambridge 213
Los Angeles 196
Council Bluffs 187
Munich 185
Moscow 179
Princeton 174
Hanoi 167
Lauterbourg 167
Medford 148
Tokyo 142
New York 128
Ann Arbor 111
Abidjan 98
San Diego 92
Helsinki 85
Jacksonville 85
São Paulo 84
Florence 79
Rome 78
Shanghai 69
Boston 63
Melbourne 62
Milan 59
Kent 57
Mumbai 54
Dallas 51
Chicago 50
Norwalk 44
Haiphong 39
Paris 36
Toronto 36
Bern 35
Boardman 35
Da Nang 35
Jakarta 35
Rio de Janeiro 34
Turku 33
Bengaluru 28
Izmir 28
Chennai 25
Orem 23
London 22
Biên Hòa 21
Frankfurt am Main 21
Brooklyn 20
Guangzhou 20
Hillsboro 20
Hải Dương 20
Redondo Beach 20
Tianjin 20
Baghdad 18
Belo Horizonte 18
Curitiba 18
Phoenix 18
Shenzhen 18
Tashkent 18
Andover 17
Brasília 17
Guayaquil 17
Naples 17
Campinas 16
Atlanta 15
Montreal 15
Salt Lake City 15
Lappeenranta 14
Abuja 13
Amsterdam 13
Fortaleza 13
Quito 13
San Francisco 13
Asunción 12
Bologna 12
Brussels 12
Buenos Aires 12
Charlotte 12
Nairobi 12
Poplar 12
Porto Alegre 12
Sorocaba 12
Totale 16.484
Salva come PNG Salva come JPEG
Nome #
Lesioni cutanee «specifiche» in corso di leucemia linfatica cronica. 573
Altered redox status in the blood of psoriatic patients: involvement of NADPH oxidase and role of anti-TNF-α therapy 350
CD30+ cutaneous T-cell lymphoma associated with sarcoidosis 339
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells. 327
SIRT1 regulates MAPK pathways in vitiligo skin: insight into the molecular pathways of cell survival 321
Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines 314
The involvement of Smac/DIABLO, p53, NF-kB and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligo skin: protective effects of curcumin and capsaicin 298
Ultrastructural and functional alterations of mitochondria in perilesional vitiligo skin. 280
Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment 275
Prurigo nodularis and lichen simplex chronicus. 230
Efalizumab in the treatment of psoriasis: when comorbidity is an issue. 224
New and experimental treatments of vitiligo and other hypomelanoses. 220
Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. 213
A rational approach to the treatment of vitiligo and other hypomelanoses. 206
The importance of genetical link in immuno-mediated dermatoses: psoriasis and vitiligo. 199
Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa 198
Fibroblasts to keratinocytes redox signaling: The possible role of ROS in psoriatic plaque formation 198
Psoriasis and body mass index. 190
Retrospective analysis of systemic treatments for psoriasis patients attending a Psocare center in Florence. Relevance of biological drugs use and comorbidities. 186
Circulating dendritic cell subsets in psoriatic patients before and after biologic therapy 179
Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry 177
Vogt-Koyanagi-Harada disease and vitiligo: where does the illness begin? 173
Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: An uncommon adverse effect? 172
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 172
Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience 170
Therapeutical approaches in melasma. 169
Efalizumab-induced severe thrombocytopenia can be resolved. 164
A mesenchyme-derived substrate is necessary for keratinocytes differentiation but not proliferation (Abs. 148). 164
Tuscan consensus on the diagnosis, treatment and follow-up of moderate-to-severe psoriasis 160
Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report. 159
Protease-activated receptor-2 downregulation is associated to vitiligo lesions 159
In-vivo imaging of psoriatic lesions with polarization multispectral dermoscopy and multiphoton microscopy 159
Polygenic Score: A Tool for Evaluating the Genetic Background of Sporadic Hidradenitis Suppurativa 156
Mast cells do not play a role in vitiligo 155
Unusual presentation of tuberculosis in an infliximab-treated patient--which is the correct TB screening before starting a biologic? 154
Epidemiology of Psoriasis and Psoriatic Arthritis in Italy—a Systematic Review 148
Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus 146
Treatment of Psoriasis with Efalizumab in Patients with Hepatitis C Viral Infection: Report of Five Cases. 145
A pediatric case of sclerodermatous graft-versus-host disease responsive to ultraviolet A1 phototherapy 144
Induction of CD83+ CD14+ non-dendritic antigen-presenting cells by exposure of monocytes to IFN-alpha1 142
High frequency ultrasound can detect improvement of lesions in juvenile localized scleroderma 142
The role of the dermatologist in Raynaud's Phenomenon: a clinical challenge 141
The concept of psoriatic disease: can cutaneous psoriasis any longer be separated by the systemic comorbidities? 141
Reduction in psoriasis related pruritus during biologic therapy* 141
Sequential effects of photodynamic treatment of basal cell carcinoma 140
NADPH Oxidase 4 as a Source of Oxidative Stress in Fibroblasts From Patients Affected by Psoriasis 140
Lichen planus triggered by CT-P13 and recurrence during secukinumab treatment 140
Source of oxidative stress in fibroblasts from patients affected by psoriasis 140
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice 140
Quantity, distribution and immunophenotypical modification of dendritic cells upon biological treatments in psoriasis. 138
Mental health consequences of the covid-19 pandemic long-term exposure in italian dermatologists 138
Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study 137
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 136
Scabies: should we always perform dermatoscopy? 135
Evidence for oxidative stress in the plasma of psoriatic patients: Source of ROS and results of treatments with biologics 135
Interleukin 22 early affects keratinocyte differentiation, but not proliferation, in a three-dimensional model of normal human skin. 135
Insights into the pathogenesis of HS and therapeutical approaches 133
Cutaneous hyperpigmentation induced by apremilast 133
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 133
Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars 133
Possible reconsideration of the Nail Psoriasis Severity Index (NAPSI) score 132
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study 132
Effectiveness and safety of anti-interleukin-17 therapies in elderly patients with psoriasis 132
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry 131
Intellectual Disability and Hidradenitis Suppurativa 131
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions 130
Clinical experience with the etanercept biosimilar SB4 in psoriatic patients 130
What's new in malignant melanoma - treatment 129
Alpha-smooth muscle actin axpression by fibroblasts is not a marker of hypertrophic scars in vitro (Abs. 774). 128
Hidradenitis suppurativa and associated diseases 128
Epidermal barrier reaction to an in vitro psoriatic microenvironment 128
Hidradenitis suppurativa and adalimumab in the COVID-19 era 125
Involvement of PAR-2 in vitiligo 124
Comment on “Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?” 124
Tumor necrosis factor-alpha and interleukin-17 differently affects Langerhans cell distribution and activation in an innovative three-dimensional model of normal human skin 123
Vitiligo masks malignant acanthosis nigricans in a woman with ovarian cancer 123
Safety and efficacy of HCV eradication during etanercept treatment for severe psoriasis 123
Clinical characteristics of psoriasis in inflammatory bowel disease patients 123
Morphologic and antigenic features of dendritic cells in immune-mediated dermatoses: A hypothesis of differentiation 122
Clinical evaluation of topical tacalcitol efficacy in extending the remission period between nb-UVB phototherapy cycles in psoriatic patients. 122
Effects of GM-CSF and TNF-alpha on the Langerhans cells of human epidermal sheets (Abs. 827). 122
First case of secukinumab successful therapy in a very elderly psoriatic patient 122
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders 122
Atypical mycobacteria 122
Ultrasonographic wrist and hand abnormalities in early psoriatic arthritis patients: Correlation with clinical, dermatological, serological and genetic indices 121
Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: a combined approach by QuantiFERON-TB Gold and tuberculin skin tests. 120
Intermediate filament proteins of keratinocytes under different culture conditions (Abs. 244). 119
Photodynamic therapy and apoptosis in cutaneous basal cell carcinoma (Abs 002). 117
Effect of a psoriatic microenvironment in a three-dimensional model of normal human skin 117
Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis 116
Clinical experience with infliximab biosimilar in psoriasis 116
Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis 116
Ultrasound detects occult entheseal involvement in early psoriatic arthritis independently of clinical features and psoriasis severity. 115
Factors influencing number and differentiation of Langerhans cells within epidermis (Abs P9). 115
Skin manifestations in psoriatic and hs patients in treatment with biologicals during the covid‐19 pandemic 115
Smooth-muscle actin, desmin and prolyl 4-hydroxylase in fibroblasts grown from hypertrophic scars and keloids (Abs. 99). 114
Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa 114
Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study 113
Effects of cyclosporin-A on the morphology of human Langerhans cells in cultured epidermal sheets Abs. 7). 111
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study 111
Totale 16.137
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.826
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.826
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021127 0 0 0 0 0 0 0 0 0 0 58 69
2021/20221.249 33 60 51 29 6 102 184 87 64 41 326 266
2022/20232.763 292 681 127 180 157 493 325 99 242 16 71 80
2023/2024924 38 81 186 43 36 65 49 215 18 76 75 42
2024/20257.588 323 897 536 982 2.135 829 210 378 490 181 278 349
2025/202610.056 946 1.325 1.030 1.223 1.106 290 1.023 569 1.080 881 583 0
Totale 25.976